Mosunetuzumab-axgb is granted accelerated approval for relapsed or refractory follicular lymphoma

Mosunetuzumab-axgb1 lunsumio

Share This Post

Jan 2023: Mosunetuzumab-axgb (Lunsumio, Genentech, Inc.), a bispecific CD20-directed CD3 T-cell engager for adult patients with relapsed or refractory follicular lymphoma (FL) following two or more rounds of systemic therapy, received accelerated approval from the Food and Drug Administration (FDA).

In GO29781 (NCT02500407), an open-label, multicenter, multi-cohort study, mosunetuzumab-axgb was assessed. 90 patients with relapsed or resistant FL who had had at least two prior lines of systemic therapy, including an anti-CD20 monoclonal antibody and an alkylating agent, made up the efficacy population.

Objective response rate (ORR) was the primary efficacy outcome measure and was determined by an independent review facility using non-lymphoma Hodgkin’s standard criteria (Cheson 2007). 60% of respondents provided complete responses, and the ORR was 80% (95% CI: 70, 88). The estimated median duration of response (DOR) was 22.8 months (95% CI: 10, not reached) with a median follow-up of 14.9 months among respondents, and the projected DOR rates at 12 months and 18 months were 62% and 57%, respectively.

A Boxed Warning for serious or life-threatening cytokine release syndrome is present in the prescribing material (CRS). Neurologic toxicity, infections, cytopenias, and tumour flare are among the warnings and precautions. Mosunetuzumab-axgb was administered to 218 individuals with hematologic malignancies at the recommended dose. Of these patients, 39% experienced CRS, 39% experienced neurologic toxicity (including 1% with ICANS), 17% had significant infections, and 4% experienced tumour flare. Grade 2 occurred in 15%, Grade 3 in 2%, and Grade 4 in 0.5% of CRS participants.

The most frequent adverse responses (20%) in the 218-patient pooled safety population were cytokine release syndrome, tiredness, rash, pyrexia, and headache. Lessened lymphocyte count, lessened phosphate, increased glucose, lessened neutrophil count, moreened uric acid, lessened white blood cell count, lessened haemoglobin, and lessened platelets were the most prevalent Grade 3 to 4 laboratory abnormalities (10%).

Mosunetuzumab-axgb should be administered at a dose of 1 mg on Cycle 1 Day 1, 2 mg on Cycle 1 Day 8, 60 mg on Cycle 1 Day 15, 60 mg on Cycle 2 Day 1, and 30 mg on Day 1 in future cycles. A therapy cycle lasts 21 days. Unless patients exhibit severe toxicity or disease progression, mosunetuzumab-axgb should be given for 8 cycles. Patients who have shown a full response should stop medication after 8 cycles. Unless they have worsening disease or intolerable toxicity, patients with a partial response or stable disease should continue treatment for up to 17 cycles.

View full prescribing information for Lunsumio.


Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه
Start chat
Need help with cancer treatment?
Scan the code
Welcome to CancerFax !

CancerFax is the most trusted international patient facilitator working with top cancer hospital's in the world like MD Anderson, Dana Farber, Asan, NCC Japan, Sheba, Beijing Cancer Institute and Apollo to bring you best of therapies and drugs.

Let us know what services would you like to avail?

1) Cancer treatment in the USA, Japan, Israel, India, Korea or Singapore?
2) CAR T-Cell therapy treatment
3) Cancer vaccine
4) Online video consultation
5) Proton therapy